Key Points
- CEO Emily Leproust sold 113,318 Twist Bioscience shares at an average price of $125.16, generating approximately $14.18 million. The transaction, conducted under a pre-arranged Rule 10b5-1 plan, reduced her stake by 12.16% to 818,938 shares.
- Twist Bioscience reported quarterly revenue of $118.38 million, up 23.2% year over year and above expectations, but its adjusted loss of $0.56 per share missed analyst estimates. Analysts expect a full-year loss of $2.12 per share.
- The stock was trading near its 52-week high at $125.21, while analysts maintained a consensus “Moderate Buy” rating and an average price target of $98.30.
Twist Bioscience Corporation (NASDAQ:TWST - Get Free Report) CEO Emily Leproust sold 113,318 shares of the company's stock in a transaction on Monday, August 10th. The shares were sold at an average price of $125.16, for a total value of $14,182,880.88. Following the completion of the transaction, the chief executive officer owned 818,938 shares of the company's stock, valued at $102,498,280.08. This trade represents a 12.16% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Twist Bioscience Trading Up 1.7%
Shares of Twist Bioscience stock opened at $125.21 on Thursday. The firm has a market cap of $7.85 billion, a PE ratio of -56.40 and a beta of 2.14. Twist Bioscience Corporation has a 1 year low of $23.30 and a 1 year high of $125.66. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.67 and a quick ratio of 2.38. The stock has a fifty day moving average price of $92.54 and a 200-day moving average price of $66.21.
Twist Bioscience (NASDAQ:TWST - Get Free Report) last issued its quarterly earnings results on Monday, August 3rd. The company reported ($0.56) earnings per share for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.05). The company had revenue of $118.38 million during the quarter, compared to analysts' expectations of $114.55 million. Twist Bioscience had a negative return on equity of 28.64% and a negative net margin of 31.66%.Twist Bioscience's quarterly revenue was up 23.2% compared to the same quarter last year. During the same period last year, the firm posted $0.33 earnings per share. Equities research analysts anticipate that Twist Bioscience Corporation will post -2.12 EPS for the current year.
Hedge Funds Weigh In On Twist Bioscience
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Allworth Financial LP bought a new stake in shares of Twist Bioscience in the second quarter valued at approximately $62,000. Trifecta Capital Advisors LLC purchased a new stake in shares of Twist Bioscience during the 2nd quarter valued at approximately $63,000. Western Wealth Management LLC bought a new position in Twist Bioscience in the 1st quarter worth approximately $31,000. Strs Ohio bought a new position in Twist Bioscience in the 1st quarter worth approximately $33,000. Finally, GAMMA Investing LLC grew its stake in Twist Bioscience by 24.4% in the 2nd quarter. GAMMA Investing LLC now owns 943 shares of the company's stock valued at $97,000 after buying an additional 185 shares in the last quarter.
Wall Street Analysts Forecast Growth
TWST has been the subject of a number of research reports. Canaccord Genuity Group increased their target price on shares of Twist Bioscience from $90.00 to $120.00 and gave the company a "buy" rating in a research report on Tuesday, July 14th. Leerink Partners set a $110.00 price target on shares of Twist Bioscience in a report on Thursday, July 16th. Barclays upped their price objective on Twist Bioscience from $65.00 to $95.00 and gave the company an "overweight" rating in a research note on Wednesday, June 24th. UBS Group set a $89.00 price objective on Twist Bioscience in a report on Monday, June 15th. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Twist Bioscience in a research report on Wednesday, June 24th. Eight research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $98.30.
View Our Latest Stock Report on Twist Bioscience
About Twist Bioscience
(
Get Free Report)
Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.
At the core of Twist's offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
